MUC16
Mucin-16
As of the edition of 20 October 2026, MUC16 (mucin-16, UniProt Q8WXI7) has 4 drugs tested at it and 6 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q8WXI7
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 4
- Disease areas
- Cancer; Hormones; Pregnancy and women's health; Urinary and reproductive; Digestive system
- Registered trials of its drugs
- 20
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Oregovomab | Active | Phase 3 | none listed |
| Abagovomab | Stopped | Phase 3 | none listed |
| Sofituzumab vedotin | Went quiet | Phase 1 | none listed |
| Igovomab | Withdrawn from market | No phase stated | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 3 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Roche | Route A |
| Unither Pharmaceuticals | Route A |
| Menarini | Route A |
The other 3 companies at MUC16
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at MUC16, ranked, with the facts behind eachRequest access. Nothing is shown until you do.